GCA
UTHR icon

Gideon Capital Advisors’s United Therapeutics UTHR Stock Holding History

Gideon Capital Advisors’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-3,398
Closed -$399K – 440
2019
Q1 		$399K Buy
+3,398
New +$396K 0.14% 218
2017
Q4 		– Sell
-2,972
Closed -$348K – 409
2017
Q3 		$348K Sell
2,972
-492
-14% -$62.8K 0.34% 100
2017
Q2 		$449K Sell
3,464
-2,177
-39% -$272K 0.49% 58
2017
Q1 		$764K Buy
5,641
+3,305
+141% +$501K 0.45% 40
2016
Q4 		$336K Buy
+2,336
New +$298K 0.21% 215

Other funds holding UTHR

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Gideon Capital Advisors's UTHR Position: Q2 2019 in Review

Gideon Capital Advisors sold out of United Therapeutics (UTHR) in Q2 2019, closing a stake of 3,398 shares — an estimated $399K sold.

Gideon Capital Advisors first reported a position in UTHR in Q4 2016 and held it in 5 quarters. The position peaked at $764K in Q1 2017. 320 funds tracked by Wall St. Rank hold UTHR as of Q2 2019.

  • Gideon Capital Advisors reported no remaining United Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Gideon Capital Advisors sold 3,398 United Therapeutics shares in Q2 2019, an estimated $399K.
  • Gideon Capital Advisors first reported a position in United Therapeutics in Q4 2016 and held it in 5 quarters.
  • Gideon Capital Advisors's United Therapeutics position peaked at $764K in Q1 2017.
  • 320 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2019.

Based on Gideon Capital Advisors's 13F filing for Q2 2019, filed 14 Aug 2019.